drugset
drugset / Trial / NCT03046550

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

NCT03046550 ↗

Phase 1 Completed 25 enrolled Alachua Government Services, Inc. National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedSequentialTriple-blindTreatment

Summary

This study evaluates the safety and pharmacokinetics of NTM-1634 in healthy subjects.

Timeline

Start
2017-03-20
Primary completion
2017-10-30
Completion
2017-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NTM-1634 Unknown 0.33 mg/kg Intravenous
Subject NTM-1634 Unknown 0.66 mg/kg Intravenous
Subject NTM-1634 Unknown 1 mg/kg Intravenous

Indications

No indication recorded.